R&D Views & Analysis | pharmaphorum

Views & Analysis

Digital

Nine for 2022: innovation and opportunities in healthcare

In the second part of our examination of issues that will shape the course of 2022, we’ll update the ongoing impacts of the pandemic, which have, as they did in 2021, a pervasive effect on

R&D

Nine for 2022: International issues that are compelling, new...

The year 2020 ended on a note of hope, with the 8th December vaccination of 91-year-old Margaret Keenan, the world’s first person to receive a COVID-19 vaccine outside clinical trials.

Patients

Hand flips a block changing 2021 to 2022. New year beginning. Holidays and Christmas. Trends and changes in the World. Summing work done. Build plans. New normal. Keep up with everything planned.

2021 in review: Building the framework of a patient-centric ...

Patient centricity and patient engagement have been hot topics in pharma for some time – but buzz words do not always translate into concrete action.

R&D

Young attractive female scientist holding a red transparent pill with futuristic scientific air interface with chemical formulas and research data in the foreground

Drug development and working with specialised Rare Disease n...

There are currently an estimated 300 million people living with one or more Rare Diseases across the world.

Digital

Leveraging augmented analytics to drive better business deci...

In early 2020, health officials were cautious about forecasting a COVID-19 vaccine timeline to the public, as vaccine discovery was a historically laborious process that took years (if not

R&D